XML 45 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
DODD-FRANK MANDATED PAY VERSUS PERFORMANCE DISCLOSURE
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, the Company must annually disclose in its proxy statement the relationship between Company performance and the “compensation actually paid” (“CAP”) to the Principal Executive Officer (“PEO”) and other NEOs.
The following tables and related disclosures contain information regarding PEO CAP and the average CAP to our NEOs for each of the last five years. They also provide information regarding company performance over the same periods and the relationship of CAP to company performance. For information about how the Compensation Committee seeks to align pay with performance when making compensation decisions, see “Compensation Discussion and Analysis.”
Pay Versus Performance Table
Value of Initial Fixed $100 Investment Based On:
Year
Summary Compensation Table Total for PEO1
($)
Compensation Actually Paid to PEO2,3
($)
Average Summary Compensation Table Total for Non-PEO
NEOs4
($)
Average Compensation Actually Paid to Non-PEO NEOs3,4,5
($)
Total Shareholder Return6
($)
Peer Group Total Shareholder Return7
($)
GAAP
Net Income
 (Loss)
($ in thousands)
202410,943,571 51,862,690 4,123,249 19,665,192 289 114 (913,772)
202310,411,260 17,719,035 4,169,997 7,124,646 130 115 (749,567)
20227,789,898 4,334,915 3,964,362 2,740,466 84 111 (481,534)
20217,322,642 2,807,467 3,323,439 1,870,969 114 125 (434,654)
20206,185,704 12,656,157 2,839,276 4,418,181 139 126 (294,090)
1.Reflects compensation (as reported in the Summary Compensation Table (“SCT”)) for our Chair and CEO, Mr. Lewis, who served as our PEO in all five years.
2.Calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to Mr. Lewis’s 2024 SCT total compensation as reported in the SCT for each year to determine CAP.
Year
Summary Compensation
Table Total
($)
Deductions for Reported Grant Date Fair Value of Stock AwardsA
($)
Deductions for Reported Grant Date Fair Value of Option AwardsA
($)
Additions for Pay Versus Performance Equity AdjustmentsB
($)
Compensation Actually Paid
($)
202410,943,571 (2,206,246)(6,618,734)49,744,099 51,862,690 
202310,411,260 (2,206,232)(6,616,654)16,130,661 17,719,035 
20227,789,898 (1,624,982)(4,872,967)3,042,966 4,334,915 
20217,322,642 (1,499,969)(4,499,673)1,484,467 2,807,467 
20206,185,704 (1,249,986)(3,749,998)11,470,437 12,656,157 
A.Reflects the amounts reported in the Stock Awards and Option Awards columns of the SCT.
B.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
Year
Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year
($)
Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years
($)
Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year
($)
Total Pay Versus Performance Equity AdjustmentsC
($)
202424,325,157 21,706,769 3,712,173 49,744,099 
202313,669,229 2,745,355 (283,923)16,130,661 
20226,205,073 (2,171,008)(991,099)3,042,966 
20215,178,718 (2,774,420)(919,831)1,484,467 
20207,254,113 3,693,320 523,003 11,470,437 
C.Amounts may not sum due to rounding of underlying elements for reporting purposes.
1.Measurement date equity fair values are calculated with assumptions derived on a basis consistent with those used for grant date fair value purposes. RSUs are valued based on the closing stock price on the relevant measurement date. PSUs are valued with an assumed payout factor of 0%, consistent with the assumption for ASC 718 purposes. Stock options are valued using a Black-Scholes model as at the relevant measurement dates.
2.Reflects compensation for the following non-PEO NEOs:
2022, 2023 and 2024: Ms. Bonstein, Mr. Adsett, Dr. Flammer, and Mr. Wise
2021: Ms. Bonstein, Mr. Adsett, Dr. Flammer, Ms. Schaeffer, and Ms. Pellizzari
2020: Ms. Bonstein, Mr. Adsett, Dr. Flammer, Ms. Pellizzari, and Mr. Goll
3.Average CAP for the non-PEO NEOs has been calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to average 2024 SCT total compensation for each year to determine average CAP.
Year
Average Summary Compensation Table Total
($)
Deductions for Average Reported Grant Date Fair Value of Stock Awardsa
($)
Deductions for Average Reported Grant Date Fair Value of Option Awardsa
($)
Additions for Average Pay Versus Performance Equity Adjustmentsb
($)
Average Compensation Actually Paidc
($)
20244,123,249 (749,990)(2,250,057)18,541,990 19,665,192 
20234,169,997 (978,097)(2,296,135)6,228,880 7,124,646 
20223,964,362 (765,603)(2,425,635)1,967,342 2,740,466 
20213,323,439 (662,479)(1,987,359)1,197,368 1,870,969 
20202,839,276 (324,990)(1,779,836)3,683,731 4,418,181 
a.Reflects the average amounts reported in the Stock Awards and Option Awards columns of the SCT.
b.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
Year
Average Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year
($)
Average Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years
($)
Average Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year
($)
Total Pay Versus Performance Equity Adjustmentsc
($)
20248,269,342 8,764,796 1,507,852 18,541,990 
20235,088,247 1,245,859 (105,226)6,228,880 
20223,073,419 (725,458)(380,618)1,967,342 
20212,293,306 (852,103)(243,835)1,197,368 
20202,962,880 630,498 90,353 3,683,731 
c.Amounts may not sum due to rounding of underlying elements for reporting purposes.
i.Total shareholder return is the only financial performance measure that is currently, and was through the years presented in the table, used in incentive plans to link CAP to Company performance.
ii.The Nasdaq Biotech Index is the selected Peer Group for TSR comparisons as included on the total return chart included on our Annual Report on Form 10-K for each reported year.
        
Company Selected Measure Name Total shareholder return        
Named Executive Officers, Footnote 1.Reflects compensation (as reported in the Summary Compensation Table (“SCT”)) for our Chair and CEO, Mr. Lewis, who served as our PEO in all five years.
2.Reflects compensation for the following non-PEO NEOs:
2022, 2023 and 2024: Ms. Bonstein, Mr. Adsett, Dr. Flammer, and Mr. Wise
2021: Ms. Bonstein, Mr. Adsett, Dr. Flammer, Ms. Schaeffer, and Ms. Pellizzari
        
Peer Group Issuers, Footnote
ii.The Nasdaq Biotech Index is the selected Peer Group for TSR comparisons as included on the total return chart included on our Annual Report on Form 10-K for each reported year.
        
PEO Total Compensation Amount $ 10,943,571 $ 10,411,260 $ 7,789,898 $ 7,322,642 $ 6,185,704
PEO Actually Paid Compensation Amount $ 51,862,690 17,719,035 4,334,915 2,807,467 12,656,157
Adjustment To PEO Compensation, Footnote
2.Calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to Mr. Lewis’s 2024 SCT total compensation as reported in the SCT for each year to determine CAP.
Year
Summary Compensation
Table Total
($)
Deductions for Reported Grant Date Fair Value of Stock AwardsA
($)
Deductions for Reported Grant Date Fair Value of Option AwardsA
($)
Additions for Pay Versus Performance Equity AdjustmentsB
($)
Compensation Actually Paid
($)
202410,943,571 (2,206,246)(6,618,734)49,744,099 51,862,690 
202310,411,260 (2,206,232)(6,616,654)16,130,661 17,719,035 
20227,789,898 (1,624,982)(4,872,967)3,042,966 4,334,915 
20217,322,642 (1,499,969)(4,499,673)1,484,467 2,807,467 
20206,185,704 (1,249,986)(3,749,998)11,470,437 12,656,157 
A.Reflects the amounts reported in the Stock Awards and Option Awards columns of the SCT.
B.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
Year
Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year
($)
Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years
($)
Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year
($)
Total Pay Versus Performance Equity AdjustmentsC
($)
202424,325,157 21,706,769 3,712,173 49,744,099 
202313,669,229 2,745,355 (283,923)16,130,661 
20226,205,073 (2,171,008)(991,099)3,042,966 
20215,178,718 (2,774,420)(919,831)1,484,467 
20207,254,113 3,693,320 523,003 11,470,437 
C.Amounts may not sum due to rounding of underlying elements for reporting purposes.
        
Non-PEO NEO Average Total Compensation Amount $ 4,123,249 4,169,997 3,964,362 3,323,439 2,839,276
Non-PEO NEO Average Compensation Actually Paid Amount $ 19,665,192 7,124,646 2,740,466 1,870,969 4,418,181
Adjustment to Non-PEO NEO Compensation Footnote
3.Average CAP for the non-PEO NEOs has been calculated in accordance with Item 402(v)(2) of Regulation S-K. The following adjustments were made to average 2024 SCT total compensation for each year to determine average CAP.
Year
Average Summary Compensation Table Total
($)
Deductions for Average Reported Grant Date Fair Value of Stock Awardsa
($)
Deductions for Average Reported Grant Date Fair Value of Option Awardsa
($)
Additions for Average Pay Versus Performance Equity Adjustmentsb
($)
Average Compensation Actually Paidc
($)
20244,123,249 (749,990)(2,250,057)18,541,990 19,665,192 
20234,169,997 (978,097)(2,296,135)6,228,880 7,124,646 
20223,964,362 (765,603)(2,425,635)1,967,342 2,740,466 
20213,323,439 (662,479)(1,987,359)1,197,368 1,870,969 
20202,839,276 (324,990)(1,779,836)3,683,731 4,418,181 
a.Reflects the average amounts reported in the Stock Awards and Option Awards columns of the SCT.
b.The pay versus performance equity adjustments reflect the aggregated sum of the following values for the respective years.
Year
Average Year-End Fair Value of Outstanding and Unvested Equity Awards Granted in the Covered Year
($)
Average Year Over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years
($)
Average Year Over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Covered Year
($)
Total Pay Versus Performance Equity Adjustmentsc
($)
20248,269,342 8,764,796 1,507,852 18,541,990 
20235,088,247 1,245,859 (105,226)6,228,880 
20223,073,419 (725,458)(380,618)1,967,342 
20212,293,306 (852,103)(243,835)1,197,368 
20202,962,880 630,498 90,353 3,683,731 
c.Amounts may not sum due to rounding of underlying elements for reporting purposes.
        
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid Versus Company Performance
The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to the cumulative TSR of Insmed. In addition, it compares the cumulative TSR of Insmed to our selected peer group, the Nasdaq Biotech Index.
4398046525296
        
Compensation Actually Paid vs. Net Income
Compensation Actually Paid Versus Company Performance
The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to GAAP net income (loss). Insmed does not consider GAAP net income (loss) as a relevant measure for determining our executive compensation given the lifecycle stage of our company. The movement in CAP across the four-year time horizon does not move meaningfully or deliberately in relation to the reported GAAP net income (loss).
4398046525305
        
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid Versus Company Performance
The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to the cumulative TSR of Insmed. In addition, it compares the cumulative TSR of Insmed to our selected peer group, the Nasdaq Biotech Index.
4398046525296
        
Total Shareholder Return Vs Peer Group
Compensation Actually Paid Versus Company Performance
The following graph visually describes the relationship between CAP to our PEO and the average CAP to our non-PEO NEOs, to the cumulative TSR of Insmed. In addition, it compares the cumulative TSR of Insmed to our selected peer group, the Nasdaq Biotech Index.
4398046525296
        
Tabular List, Table
Tabular List of Company Performance Measures
As further described in our CD&A, we believe that the compensation opportunities for our NEOs should be predominantly variable with a significant portion in the form of short-term and long-term incentives. Given the current life-cycle stage of Insmed, financial measures do not feature meaningfully in our incentive plan design, which instead focuses on pipeline progress across our four pillars and stock price performance. For the fiscal year ending December 31, 2024, the only financial performance measure used to link CAP to our NEOs to company performance was total shareholder return. Total shareholder return was used on a relative basis to assess performance in respect of the PSUs, which were unvested and outstanding, at the conclusion of the performance period. As a result of total shareholder return already being included in the pay versus performance table, no company-selected measure is reported.
TABULAR LIST OF MOST IMPORTANT MEASURES
(1)Total Shareholder Return
       
Total Shareholder Return Amount $ 289 130 84 114 139
Peer Group Total Shareholder Return Amount 114 115 111 125 126
Net Income (Loss) $ (913,772,000) $ (749,567,000) $ (481,534,000) $ (434,654,000) (294,090,000)
PEO Name Mr. Lewis Mr. Lewis Mr. Lewis Mr. Lewis  
Measure:: 1          
Pay vs Performance Disclosure          
Name Total Shareholder Return        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 49,744,099 $ 16,130,661 $ 3,042,966 $ 1,484,467 11,470,437
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 24,325,157 13,669,229 6,205,073 5,178,718 7,254,113
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 21,706,769 2,745,355 (2,171,008) (2,774,420) 3,693,320
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,712,173 (283,923) (991,099) (919,831) 523,003
PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,206,246) (2,206,232) (1,624,982) (1,499,969) (1,249,986)
PEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (6,618,734) (6,616,654) (4,872,967) (4,499,673) (3,749,998)
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 18,541,990 6,228,880 1,967,342 1,197,368 3,683,731
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 5,088,247 3,073,419 2,293,306 2,962,880  
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,245,859 (725,458) (852,103) 630,498  
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (105,226) (380,618) (243,835) 90,353  
Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Stock Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (749,990) (978,097) (765,603) (662,479) (324,990)
Non-PEO NEO | Aggregate Grant Date Fair Value Of Equity Award Amounts Reported In Summary Compensation Table, Option Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,250,057) (2,296,135) (2,425,635) (1,987,359) $ (1,779,836)
Non-PEO NEO | Pay Versus Performance Equity Adjustments [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 6,228,880 $ 1,967,342 $ 1,197,368 $ 3,683,731